Oramed Pharma (ORMP) Gains After Reporting Top-Line Data From Phase 2a ORMD-0801 Trial
Tweet Send to a Friend
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) today reported positive top-line clinical results from its Phase IIa clinical trial of ORMD-0801, the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
